RxDoctor Payments Data

Damon Raskin, MD

Internal Medicine · Pacific Palisades, CANPI 1528254133

Payments from drug & device makers

$406,899in general payments, 2019–2025

Across 2,022 payments — averaging $201.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$127K
  • Idorsia Pharmaceuticals US Inc$85K
  • Indivior Inc.$64K
  • Alkermes, Inc.$41K
  • Gilead$36K
  • MDD US Operations, LLC$13K
  • plus $39K from 54 others
$150in research payments, 2019–2025

Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$150

What the payments were for

  • Consulting fees$49,61112%
  • Speaking & faculty fees$255,33563%
  • Travel & lodging$65,60016%
  • Food & beverage$36,0689%
  • Education$2850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eisai Inc.287$127,259
Idorsia Pharmaceuticals US Inc187$85,173
Indivior Inc.215$64,435
Alkermes, Inc.95$41,023
Gilead77$36,239
MDD US Operations, LLC30$13,122
Daiichi Sankyo Inc.15$7,938
Eli Lilly3$7,533
AbbVie(2 entities)290$5,144
Pfizer69$1,451
Biohaven Pharmaceuticals, Inc.8$1,350
Amgen(2 entities)72$1,266
Takeda Pharmaceuticals U.S.A., Inc.52$1,196
GSK42$940
Novo Nordisk50$939
Lilly USA, LLC41$913
Otsuka America Pharmaceutical, Inc.37$885
Lundbeck LLC31$751
AstraZeneca28$581
Merck26$531
Axsome Therapeutics, Inc.15$449
Bausch Health US, LLC19$418
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC22$406
Johnson & Johnson20$371
Almatica Pharma LLC17$362
Shire North American Group Inc1$350
Currax Pharmaceuticals LLC19$316
Antares Pharma, Inc.14$242
E.r. Squibb & Sons, L.L.C.13$233
Novartis9$219
Avanir Pharmaceuticals, Inc.10$214
Harmony Biosciences LLC4$212
Biohaven Pharmaceutical Holding Company Ltd.9$209
Corium, LLC11$205
Endo Pharmaceuticals Inc.10$203
Astellas Pharma US Inc7$189
Viiv Healthcare Company5$160
Vivus LLC7$145
Boehringer Ingelheim6$135
Upsher-smith Laboratories LLC6$135
Mylan Specialty L.p.6$134
Teva Pharmaceuticals USA, Inc.6$131
Supernus Pharmaceuticals, Inc.7$128
Exact Sciences7$128
Ardelyx, Inc.4$126
Amarin Pharma, Inc.7$122
USWM, LLC6$118
Jazz Pharmaceuticals Inc.6$117
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$117
Sunovion Pharmaceuticals Inc.6$113
Myriad Women's Health, Inc.1$98
Halozyme Inc4$87
Genentech USA, Inc.4$79
Acerus Pharmaceuticals Corporation4$76
Arbor Pharmaceuticals, Inc.4$74
Phathom Pharmaceuticals, Inc.3$71
Regeneron Healthcare Solutions, Inc.3$71
Alfasigma USA, Inc.3$67
Braeburn Inc.2$61
Tris Pharma Inc3$58

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$406,899 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$299,355
Medicare patients
553
Services billed
4,389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide65$65,853
Trelegy ElliptaFluticasone/Umeclidin/Vilanter79$61,785
OzempicSemaglutide54$58,024
EliquisApixaban58$50,754
JardianceEmpagliflozin55$41,097
DayvigoLemborexant107$36,265
MyrbetriqMirabegron46$35,862
RexultiBrexpiprazole15$31,457
AveedTestosterone Undecanoate14$26,996
Repatha SureclickEvolocumab41$26,966
GemtesaVibegron46$25,163
TrintellixVortioxetine Hydrobromide30$21,098
FarxigaDapagliflozin Propanediol21$14,405
LinzessLinaclotide26$13,764
SynthroidLevothyroxine Sodium191$13,219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$913$65,85365 claims
GSKTrelegy Ellipta$940$61,78579 claims
Novo NordiskOzempic$939$58,02454 claims
PfizerEliquis, Premarin$1,451$55,18969 claims
Boehringer IngelheimJardiance$135$41,09755 claims
Eisai Inc.Dayvigo$127,259$36,265107 claims
Astellas Pharma US IncMyrbetriq$189$35,86246 claims
Otsuka America Pharmaceutical, Inc.Rexulti$885$31,45715 claims
Endo Pharmaceuticals Inc.Aveed$203$26,99614 claims
AbbVieLinzess, Synthroid$5,144$26,983217 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$1,196$21,09830 claims
MerckBelsomra, Janumet$531$18,79840 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Pacific Palisades

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →